CRVO
CervoMed Inc.
Key Financials
Net Income
$-26966367
↓ 65.5%
Operating Income
$-28294877
↓ 55.2%
Gross Profit
$-1738134
↓ 921.2%
Revenue
$4.0M
↓ 58.9%
Total Assets
$22.9M
↓ 46.9%
EPS (Diluted)
$2038891.00
↓ 97.9%
Total Liabilities
$4.7M
↑ 20.0%
Shareholders' Equity
$18.2M
↓ 53.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| 8-K | 8/10/2026 | View on SEC |
| S-8 | 8/7/2026 | View on SEC |
| 10-Q | 8/7/2026 | View on SEC |
| 8-K | 8/4/2026 | View on SEC |
| 8-K | 7/14/2026 | View on SEC |
| EFFECT | 7/10/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CRVO |
| Company Name | CervoMed Inc. |
| CIK | 1053691 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (617) 744-4400 |